# US 2017/0253662 A1 · Dosage and administration of anti-egfr therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253662 A1
- Document ID: US20170253662A1
- Status: Published application
- Kind: A1
- Application number: 15/598,116
- Filed: 2017-05-17
- Published: 2017-09-07
- Earliest claimed: 2014-05-14
- Assignees: Merrimack Pharmaceuticals, Inc.
- Applicants: Merrimack Pharmaceuticals, Inc.
- Inventors: Jeffrey David KEARNS; Beni B. WOLF
- Web page: https://patentgrep.com/patent/US20170253662A1

## CPC

- C07K 16/32: against translation products of oncogenes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/30: from tumour cells
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.

## Claims

### Claim 1

A method of administering a mixture of two or more monoclonal anti-EGFR antibodies to a human cancer patient,
the method comprising initially administering the mixture to the patient as a first and a second intravenous infusion during an initial two week treatment cycle, comprising a first week and a second week, wherein:
i. a first dose of the mixture of anti-EGFR antibodies is administered during the first week at a rate of X mg/hour for a first ½ hour, immediately followed by a rate of 2X mg/hour for a second ½ hour, immediately followed by a rate of 4X mg/hour until all of the first dose has been administered; and
ii. a second dose of the mixture of anti-EGFR antibodies is administered during the second week at a rate of X mg/hour for a first ½ hour, immediately followed by a rate of 2X mg/hour for a second ½ hour, immediately followed by a rate of 4X mg/hour for a third ½ hour, immediately followed by a rate of 8X mg/hour until all of the second dose has been administered.

### Claim 2 (depends on 1)

The method of claim 1, wherein prior to each infusion of the mixture of anti-EGFR antibodies, diphenhyradmine is administered to the patient orally or intravenously at a dose of 25 mg-50 mg.

### Claim 3 (depends on 1)

The method of claim 1, wherein prior to each infusion of the mixture of anti-EGFR antibodies, methylprednisolone is administered to the patient intravenously at a dose of 25 mg-125 mg.

### Claim 4 (depends on 1)

The method of claim 1, wherein prior to each infusion of anti-EGFR antibodies, acetaminophen is administered to the patient at a dose of 650 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mixture of monoclonal anti-EGFR antibodies is administered to a human cancer patient diagnosed with colorectal cancer, head and neck cancer, non-small cell lung cancer, gastric cancer, breast cancer, endometrial cancer, ovarian cancer, cervical cancer, bladder cancer, esophageal cancer, brain cancer, liver cancer, pancreatic cancer, or squamous cell carcinoma.

### Claim 6 (depends on 1)

The method of claim 1, wherein X is 25.

### Claim 7 (depends on 1)

The method of claim 1, wherein the first dose is about 225 mg or is about 3 mg/kg.

### Claim 8 (depends on 1)

The method of claim 1, wherein the second dose is about 450 mg or is about 6 mg/kg.

### Claim 9 (depends on 1)

The method of claim 1, wherein the mixture of anti-EGFR antibodies consists of anti-EGFR antibodies that specifically bind to two or more different epitopes of the extracellular domain of EGFR.

### Claim 10 (depends on 1)

The method of claim 1, wherein the mixture comprises two or more anti-EGFR antibodies selected from the group consisting of:
i) a first antibody comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 7, 8 and 9 respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 10, 11 and 12 respectively;
ii) a second antibody comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 13, 14 and 15 respectively and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 16, 17, and 18 respectively; and
iii) a third antibody comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 19, 20 and 21 respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 22, 23 and 24 respectively.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mixture comprises three anti-EGFR antibodies.

### Claim 12 (depends on 11)

The method of claim 11, wherein the mixture of three anti-EGFR antibodies is MM-151 and the first antibody, the second antibody, and the third antibody are formulated in a mixture at a molar ratio to each other of 2:2:1, respectively.

### Claim 13 (depends on 1)

The method of claim 1, wherein the mixture of monoclonal anti-EGFR antibodies is administered in further combination with liposomal irinotecan.

### Claim 14 (depends on 1)

The method of claim 1, wherein, if the patient tolerates the initial cycle, the at least one cycle further comprises at least one subsequent treatment cycle, each subsequent treatment cycle comprising at least one administration of the mixture of anti-EGFR antibodies at a third dose.

### Claim 15 (depends on 14)

The method of claim 14, wherein the third dose of the mixture of anti-EGFR antibodies is administered at a rate of 2X mg/hour for a first ½ hour, immediately followed by a rate of 4X mg/hour for a second ½ hour, immediately followed by a rate of 8X mg/hour for a third ½ hour, immediately followed by a rate of 16X mg/hour until all of the third dose has been administered.

### Claim 16 (depends on 14)

The method of claim 14, wherein the at least one subsequent treatment cycle has a duration of three weeks or four weeks.

### Claim 17 (depends on 14)

The method of claim 14, wherein the third dose of the mixture of anti-EGFR antibodies is 4.5 mg/kg, 6 mg/kg, 7.5 mg/kg, 9 mg/kg, 10 mg/kg, 10.5 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 18 mg/kg, and 20 mg/kg; and is administered weekly, bi-weekly or tri-weekly.

### Claim 18

A method of administering a mixture of two or more monoclonal anti-EGFR antibodies to a human cancer patient,
the method comprising initially administering the mixture to the patient as a first and a second intravenous infusion over a two week cycle as priming doses in sequence as set forth in the following table:
Infusion
Mixture
Cumulative
Rate
Infusion Rate
Infused
Mixture
Infusion
Sequence1
(mg/hr)
(mg)
Infused (mg)
1st Infusion
1st Rate
25
12.5
12.5
(Priming Week 1)
2nd Rate
50
25.0
37.5
3rd Rate
100
187.5
225.0
2nd Infusion
1st Rate
25
12.5
12.5
(Priming Week 2)
2nd Rate
50
25.0
37.5
3rd Rate
100
50.0
87.5
4th Rate
200
362.5
450
1per infusion
wherein the 1st infusion of the mixture is administered during the priming week 1 at the 1st rate for a ½ hour, immediately followed by the 2nd rate for a second ½ hour, immediately followed by the 3rd rate until all of the first dose and 225 mg of mixture has been administered;
wherein the 2nd infusion of the mixture is administered during priming week 2 at the 1st rate for a ½ hour, immediately followed by the 2nd rate for the second ½ hour, immediately followed by the 3rd rate for a ½ hour, immediately followed by the 4th rate until all of the first dose and 450 mg of mixture has been administered; and
wherein the mixture of monoclonal IgG1 anti-EGFR antibodies is administered to a human cancer patient diagnosed with colorectal cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein prior to each infusion of the mixture of anti-EGFR antibodies, diphenhydramine is administered to the patient orally or intravenously at a dose of 25 mg-50 mg.

### Claim 20 (depends on 18)

The method of claim 18, wherein prior to each infusion of the mixture of anti-EGFR antibodies, methylprednisolone is administered to the patient intravenously at a dose of 25 mg-125 mg.

### Claim 21 (depends on 18)

The method of claim 18, wherein prior to each infusion of the mixture of anti-EGFR antibodies, acetaminophen is administered to the patient at a dose of 650 mg.

### Claim 22 (depends on 18)

The method of claim 18, wherein the method comprises administering the mixture of anti-EGFR antibodies in combination with liposomal irinotecan.

### Claim 23 (depends on 18)

The method of claim 18, wherein the mixture comprises two or more anti-EGFR antibodies selected from the group consisting of:
i) a first monoclonal antibody comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NO: 7, 8 and 9 respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NO: 10, 11 and 12 respectively;
ii) a second monoclonal antibody comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NO: 13, 14 and 15 respectively and light chain CDRs 1, 2 and 3 set forth in SEQ ID NO: 16, 17, and 18 respectively; and
iii) a third monoclonal antibody comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NO: 19, 20 and 21 respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NO: 22, 23 and 24 respectively.

### Claim 24 (depends on 23)

The method of claim 23, wherein the mixture comprises three anti-EGFR antibodies.

### Claim 25 (depends on 24)

The method of claim 24, wherein the mixture of three monoclonal anti-EGFR antibodies is MM-151 and the first antibody, the second antibody, and the third antibody are formulated in a mixture at a molar ratio to each other of 2:2:1, respectively.
